BTG logo

BTG - BTG Share Price

840p 0.0  0.0%

Last Trade - 16/08/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £686.0m
Position in Universe th / 1841
Bullish
Bearish
Unlock BTG Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BTG Revenue Unlock BTG Revenue

Net Income

BTG Net Income Unlock BTG Revenue

Normalised EPS

BTG Normalised EPS Unlock BTG Revenue

PE Ratio Range

BTG PE Ratio Range Unlock BTG Revenue

Dividend Yield Range

BTG Dividend Yield Range Unlock BTG Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BTG EPS Forecasts Unlock BTG Revenue
Profile Summary

BTG Limited, formerly BTG plc, is medical device development and healthcare service provider. It provides Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care and licensing business. It operates through three segments: Interventional Medicine, Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.

Directors
Last Annual March 31st, 2019
Last Interim March 31st, 2019
Incorporated December 12, 1991
Public Since June 28, 1995
No. of Shareholders: 7,581
No. of Employees: 1,547
Sector Healthcare
Industry Pharmaceuticals
Index ,
Exchange London Stock Exchange
Shares in Issue 388,257,291
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BTG Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to BTG
© Stockopedia 2019, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.